Business UpdateJun 4, 2026, 08:31 AM
RenovoRx CEO to Present Business Update, Record Q1 Revenue, Trial Progress
AI Summary
RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026. He will discuss the company's record first quarter 2026 revenue of $563,000, driven by growing demand for RenovoCath, and the expected completion of enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026. Mr. Bagai will also provide updates on the trial's progress and the recent FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer, which is the company's third overall ODD.
Key Highlights
- CEO Shaun Bagai to present at iAccess Alpha Virtual Conference on June 23, 2026.
- Discussing record Q1 2026 RenovoCath revenue of $563,000.
- Anticipates completing Phase III TIGeR-PaC trial enrollment by end of June 2026.
- Final TIGeR-PaC trial data expected in mid-to-late 2027.
- Received FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer (third ODD).
- ODD provides seven years of market exclusivity upon approval.
- RenovoCath sales for full year 2025 were approximately $1.1 million.
Price Impact
More from RNXT